Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


CMR Surgical completes $240m series C operation
Cambridge Innovation Capital has returned a second time to back a $240m series C for CMR Surgical, helping bring the surgical robotics company's total funding to $386m.
Trifacta wrangles $100m
Trifacta, co-founded by Stanford and UC Berkeley researchers, has attracted nearly a dozen investors for a round that brought its total funding to $224m.
CAS helps GKHT source $154m
Cash Capital has contributed to a a series C round for medical supplies provider GKHT, established as an affiliate of the Chinese Academy of Sciences-owned Osic Holding Group.
Passage Bio packs in another $110m
University of Pennsylvania-allied CNS disease therapy developer Passage Bio lured contributions from investors including Lilly Asia Ventures, which also featured in its $116m series A earlier this year.
Achilles Therapeutics accesses $120m
UCL and Francis Crick-founded Achilles has raised series B funding at a reported $228m valuation and will now look to advance lung cancer and melanoma treatments.
Kronos cracks $105m series A
GV contributed to a round for MIT-founded small molecule cancer drug spinout Kronos Bio, adding to $18m raised by the latter 14 months ago.
Recursion reconciles $121m
The series C for Utah-founded drug discovery platform creator Recursion included capital from University of Minnesota and Texas Tech University System.
Biontech completes $325m series B
Fidelity Management & Research has led a $325m series B round for Biontech, a spinout of Johannes Gutenberg University Mainz whose backers also include Sanofi and Pfizer.

Other News

Revolution celebrates $100m
Third Rock contributed to a $100m series C round for UIC's cancer drug developer Revolution that brought its total to $226m.
Tier IV tears it up to raise $105m
Sompo Japan Nipponkoa led the Utec-backed autonomous vehicle software developer's series A round, which included Yamaha Motor, Aisan Technology and existing investor KDDI.
Bayer leads Century to $250m
Immuno-oncology therapy developer Century Therapeutics has emerged from stealth, having been established by Versant Ventures to advance Stanford and Harvard research.
CFS sparks $115m series A close
Just over a year after securing an initial $50m tranche backed by Eni, MIT’s Commonwealth Fusion Systems has closed its series A round with $115m in capital.
CureFit stretches to $120m in Unilever-backed round
CureFit had held discussions with SoftBank Vision Fund over a $200m investment, but Unilever Ventures has instead stepped up as part of a $120m round.
CureFit starts training for $200m round
SoftBank is reportedly considering an investment of between $200m and $350m in CureFit, whose existing investors include the University of California-backed UC-RNT Fund.

Editor's Picks

Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Immunocore smashes European biotech records
Immunotherapy firm Immunocore, which started life at Oxford University, raises the largest biotech round in European history.
test reg